Literature DB >> 24184714

Prophylactic systemic P2X7 receptor blockade prevents experimental colitis.

Carla Caldas Marques1, Morgana T Castelo-Branco, Rodrigo G Pacheco, Fernanda Buongusto, Alyson do Rosário, Alberto Schanaider, Robson Coutinho-Silva, Heitor S P de Souza.   

Abstract

BACKGROUND: The P2X7 receptor (P2X7-R) is a non-selective adenosine triphosphate-gated cation channel present in epithelial and immune cells, and involved in inflammatory response. Extracellular nucleotides released in conditions of cell stress or inflammation may function as a danger signal alerting the immune system from inflammation. We investigated the therapeutic action of P2X7-R blockade in a model of inflammatory bowel disease.
METHODS: Rats with trinitrobenzene sulfonic (TNBS) acid-induced colitis were treated with the P2X7-R antagonists A740003 or brilliant blue G (BBG) through intra-peritoneal (IP) or intra-colonic (IC) injection prior to colitis induction. Clinical and endoscopic follow-up, histological scores, myeloperoxidase activity, densities of collagen fibers and goblet cells were evaluated. P2X7-R expression, NF-kappa B and Erk activities, and densities of T-cells and macrophages were analyzed by immunoperoxidase. The inflammatory response was determined by measuring inflammatory cytokines in cultures of colon explants, by enzyme-linked immunosorbent assay. Colonic apoptosis was determined by the TUNEL assay.
RESULTS: IP-BBG significantly attenuated the severity of colitis, myeloperoxidase activity, collagen deposition, densities of lamina propria T-cells and macrophages, while maintaining goblet cell densities. IP-BBG inhibited the increase in P2X7-R expression in parallel with apoptotic rates. TNF-α and interleukin-1β stabilized in low levels, while TGF-β and interleukin-10 did not change following IP-BBG-therapy. Colonic NF-kappa-B and Erk activation were significantly lower in IP-BBG-treated animals. Prophylactic IP-A740003 also protected rats against the development of TNBS-colitis.
CONCLUSIONS: Prophylactic systemic P2X7-R blockade is effective in the prevention of experimental colitis, probably due to a systemic anti-inflammatory action, interfering with a stress-inflammation amplification loop mediated by P2X7-R.
© 2013.

Entities:  

Keywords:  Apoptosis; Brilliant blue G; Innate immunity; P2X7-R; P2X7-R blockade; TNBS-induced colitis

Mesh:

Substances:

Year:  2013        PMID: 24184714     DOI: 10.1016/j.bbadis.2013.10.012

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  28 in total

Review 1.  The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory Diseases.

Authors:  Luca Antonioli; Corrado Blandizzi; Pál Pacher; György Haskó
Journal:  Pharmacol Rev       Date:  2019-07       Impact factor: 25.468

Review 2.  Understanding the Holobiont: How Microbial Metabolites Affect Human Health and Shape the Immune System.

Authors:  Thomas Siegmund Postler; Sankar Ghosh
Journal:  Cell Metab       Date:  2017-06-15       Impact factor: 27.287

3.  Connexin-purinergic signaling in enteric glia mediates the prolonged effect of morphine on constipation.

Authors:  Sukhada Bhave; Aravind Gade; Minho Kang; Kurt F Hauser; William L Dewey; Hamid I Akbarali
Journal:  FASEB J       Date:  2017-03-09       Impact factor: 5.191

4.  P2X₇ receptor of rat dorsal root ganglia is involved in the effect of moxibustion on visceral hyperalgesia.

Authors:  Shuangmei Liu; Qingming Shi; Qicheng Zhu; Ting Zou; Guilin Li; An Huang; Bing Wu; Lichao Peng; Miaomiao Song; Qin Wu; Qiuyu Xie; Weijian Lin; Wei Xie; Shiyao Wen; Zhedong Zhang; Qiulan Lv; Lifang Zou; Xi Zhang; Mofeng Ying; Guodong Li; Shangdong Liang
Journal:  Purinergic Signal       Date:  2014-12-20       Impact factor: 3.765

5.  Inhibition of P2X7 receptors by Lu AF27139 diminishes colonic hypersensitivity and CNS prostanoid levels in a rat model of visceral pain.

Authors:  Roland G W Staal; Adarsh Gandhi; Hua Zhou; Manuel Cajina; Anne-Marie Jacobsen; Sara Hestehave; Allen Hopper; Suresh Poda; Gamini Chandresana; Stevin H Zorn; Brian Campbell; Marta Segerdahl; Thomas Mӧller; Gordon Munro
Journal:  Purinergic Signal       Date:  2022-08-24       Impact factor: 3.950

Review 6.  Gut mucosal DAMPs in IBD: from mechanisms to therapeutic implications.

Authors:  R K Boyapati; A G Rossi; J Satsangi; G-T Ho
Journal:  Mucosal Immunol       Date:  2016-03-02       Impact factor: 7.313

Review 7.  Pathophysiological role of extracellular purinergic mediators in the control of intestinal inflammation.

Authors:  Yosuke Kurashima; Hiroshi Kiyono; Jun Kunisawa
Journal:  Mediators Inflamm       Date:  2015-04-07       Impact factor: 4.711

Review 8.  Cell death and inflammatory bowel diseases: apoptosis, necrosis, and autophagy in the intestinal epithelium.

Authors:  Tiago Nunes; Claudio Bernardazzi; Heitor S de Souza
Journal:  Biomed Res Int       Date:  2014-07-14       Impact factor: 3.411

9.  Anti-fibrogenic effects of the anti-microbial peptide cathelicidin in murine colitis-associated fibrosis.

Authors:  Jun Hwan Yoo; Samantha Ho; Deanna Hoang-Yen Tran; Michelle Cheng; Kyriaki Bakirtzi; Yuzu Kukota; Ryan Ichikawa; Bowei Su; Diana Hoang-Ngoc Tran; Tressia C Hing; Irene Chang; David Q Shih; Richard E Issacson; Richard L Gallo; Claudio Fiocchi; Charalabos Pothoulakis; Hon Wai Koon
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2015-01

10.  Involvement of the P2X7 purinergic receptor in colonic motor dysfunction associated with bowel inflammation in rats.

Authors:  Luca Antonioli; Maria Cecilia Giron; Rocchina Colucci; Carolina Pellegrini; Deborah Sacco; Valentina Caputi; Genny Orso; Marco Tuccori; Carmelo Scarpignato; Corrado Blandizzi; Matteo Fornai
Journal:  PLoS One       Date:  2014-12-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.